JP2021526845A5 - - Google Patents

Info

Publication number
JP2021526845A5
JP2021526845A5 JP2021500908A JP2021500908A JP2021526845A5 JP 2021526845 A5 JP2021526845 A5 JP 2021526845A5 JP 2021500908 A JP2021500908 A JP 2021500908A JP 2021500908 A JP2021500908 A JP 2021500908A JP 2021526845 A5 JP2021526845 A5 JP 2021526845A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
pharmaceutical composition
sequence described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021500908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526845A (ja
JP7534281B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/069035 external-priority patent/WO2020012038A1/en
Publication of JP2021526845A publication Critical patent/JP2021526845A/ja
Publication of JP2021526845A5 publication Critical patent/JP2021526845A5/ja
Priority to JP2024125676A priority Critical patent/JP2024160275A/ja
Application granted granted Critical
Publication of JP7534281B2 publication Critical patent/JP7534281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500908A 2018-07-13 2019-07-15 Cd38抗体を使用したトロゴサイトーシスを介した治療 Active JP7534281B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125676A JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862697719P 2018-07-13 2018-07-13
US62/697,719 2018-07-13
US201962848861P 2019-05-16 2019-05-16
US62/848,861 2019-05-16
PCT/EP2019/069035 WO2020012038A1 (en) 2018-07-13 2019-07-15 Trogocytosis-mediated therapy using cd38 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125676A Division JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Publications (3)

Publication Number Publication Date
JP2021526845A JP2021526845A (ja) 2021-10-11
JP2021526845A5 true JP2021526845A5 (cg-RX-API-DMAC7.html) 2022-07-21
JP7534281B2 JP7534281B2 (ja) 2024-08-14

Family

ID=67441085

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500908A Active JP7534281B2 (ja) 2018-07-13 2019-07-15 Cd38抗体を使用したトロゴサイトーシスを介した治療
JP2024125676A Pending JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125676A Pending JP2024160275A (ja) 2018-07-13 2024-08-01 Cd38抗体を使用したトロゴサイトーシスを介した治療

Country Status (5)

Country Link
US (1) US20240254252A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820890A1 (cg-RX-API-DMAC7.html)
JP (2) JP7534281B2 (cg-RX-API-DMAC7.html)
MA (1) MA53123A (cg-RX-API-DMAC7.html)
WO (1) WO2020012038A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7880817B2 (ja) 2019-11-06 2026-06-26 ジェンマブ ビー.ブイ. 抗体変種の組み合わせおよびその使用
MX2022008050A (es) * 2020-01-16 2022-07-27 Genmab As Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas.
CN115667532A (zh) * 2020-06-02 2023-01-31 百奥赛图(北京)医药科技股份有限公司 具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
WO2023192321A2 (en) * 2022-03-28 2023-10-05 Vygen-Bio, Inc. Genetically engineered antibody resistant (gear) cells for adoptive cellular therapy
US20250382378A1 (en) 2022-10-31 2025-12-18 Genmab A/S Cd38 antibodies and uses thereof
US20250296989A1 (en) * 2024-03-20 2025-09-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス,インコーポレーテッド 共有結合型ダイアボディ及びその使用
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗-vegf/抗-ang-2抗體
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
BR112013002167A2 (pt) 2010-08-24 2016-05-31 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US9527927B2 (en) 2011-12-20 2016-12-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
MX387324B (es) * 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
EP3932947A1 (en) 2013-03-14 2022-01-05 Translate Bio MA, Inc. Methods and compositions for delivering mrna coded antibodies
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
JP2017513481A (ja) 2014-04-16 2017-06-01 ユーシービー バイオファルマ エスピーアールエル 多量体Fcタンパク質
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
RS63051B1 (sr) 2015-12-22 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularnu isporuku agenasa
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
EP3497120A1 (en) 2016-08-12 2019-06-19 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
EP3559248B2 (en) 2016-12-21 2024-11-20 F. Hoffmann-La Roche AG In vitro glycoengineering of antibodies
MX2019007411A (es) 2016-12-21 2019-08-29 Hoffmann La Roche Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
MX2019006123A (es) 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery

Similar Documents

Publication Publication Date Title
US11498963B2 (en) Anti-LILRB antibodies and their use in detecting and treating cancer
JP2021524276A5 (cg-RX-API-DMAC7.html)
CN110536903B (zh) 抗ox40抗体及其用途
Adler et al. Therapeutic antibodies against cancer
KR101843807B1 (ko) 암의 치료 및/또는 예방을 위한 의약품
CA2788545C (en) Pharmaceutical composition for treating and/or preventing cancer
JP7753186B2 (ja) 抗pd-1抗体およびその医学的使用
CN121021694A (zh) 结合cd123的多肽及其用途
KR20150002646A (ko) 항 fgfr2 항체
HUE030103T2 (en) A pharmaceutical composition for the treatment and / or prevention of cancer
JP2019151635A (ja) 抗fgfr2抗体と他剤の組合せ
JP2022525071A (ja) Ctla-4遮断剤とpd-1遮断剤とを含む抗癌併用療法
TW201642897A (zh) Her2結合劑治療
CN115135344A (zh) 在疗法中使用的抗体
CN111108124A (zh) 新型抗体以及treg消耗性抗体和免疫刺激性抗体的组合使用
CN120647763A (zh) 抗半乳糖凝集素-9抗体及其用途
WO2022179507A1 (en) Methods of preventing, alleviating or treating tumors
AU2021378152A1 (en) COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
JP2023089273A (ja) 自己免疫疾患治療用抗体
Wu et al. Development and characterization of 4A7: a high-affinity monoclonal antibody targeting Claudin18. 2
CN112041346B (zh) 用于与抗pd-1抗体组合的抗cd137抗体
WO2024109657A1 (zh) 抗ccr8抗体及其用途
CN114616245B (zh) 一种抗cd38的抗体及其用途
CN119894927A (zh) 经修饰的抗半乳凝素-9抗体及其用途
JP2020507576A (ja) Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物